Join the “who’s who” of the biosimilars and innovator biologics industries in Boston this June.
Biosimilars and innovator biologics are among the most groundbreaking therapies that treat many life-threatening conditions. However, even with a calendar year that included 4 FDA approvals, 3 launches in the United Sates, 2 approvals for interchangeable biosimilars, and several regulatory and legal developments, the traditional barriers continue to be complicated, interconnected, and best addressed by stakeholder collaboration.
We’ve reached an inflection point in the United States. With another major wave of loss of exclusivities of original biological medicines expected in the next five to ten years, it is imperative that industry is well prepared today. Now, more than ever, strategies to overcome these barriers are essential to improve the understanding of biosimilar products in the United States. The need for a solid guiding framework becomes more critical than ever before.
In this context, we cordially invite you to explore the contours of the rapidly changing landscape for biosimilars and innovator biologics. This June, join the “who’s who” of the biosimilars and innovator biologics industries as they gather in Boston for ACI’s 13th Annual Summit on Biosimilars & Innovator Biologics.
2022 Co-Chairs
Charles K. Sholtz, PhD, JD
Director and AGC, Manufacturing IP Lead
Intellectual Property
Genentech | A Member of the Roche Group
“With the approval of the first two interchangeable biosimilar in the past year, and several more on the horizon, we are entering a new era of biosimilar medicines in the United States. Join us as we tackle topics ranging from intellectual property, to regulatory, to antitrust, to pricing/ reimbursement, and be part of the conversation about how the industry collectively ensures that everyone with a serious disease can get the treatment they need.”
Gillian Woollett
VP, Head Regulatory Strategy and Policy
Samsung Bioepis
“While we are buffeted by international news about pandemics and wars, there remains a critically important job for us to do. And that is to make cost-effective quality medicines available to patients. Fortunately, Covid has confirmed that the science is truly a global language and biologics can be made and distributed worldwide. The regulatory and legal environments can support this or confound it. At this meeting you will see how efforts are evolving to support a fair competitive environment that encourages both originator biologics and biosimilars – after all the former are the future for the latter, and the US is the single biggest biologics market in the world by value.”
Exclusive Insights from
M. Stacey Ricci
Director, Scientific Review Staff
Office of Therapeutic Biologics and Biosimilars
U.S. Food and Drug Administration
Hon. Michelle Ankenbrand
Senior Lead Administrative Patent Judge, PTAB
USPTO
Beckey Egeland
Attorney, Bureau of Competition
U.S. FTC
CLE ACCREDITATION
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation. Learn more
Who You Will Meet
In-house counsel from branded and biosimilars companies
Government representatives from the FDA, USPTO, and the Judiciary
Leading regulatory and patent attorneys from around the country
About this Conference
Prepare to enter the next decade of this revolutionary law.
Biologics have become the fastest-growing class of therapeutic compounds. They have provided innovative treatment alternatives for people who suffer from some of the most serious medical conditions known to man. The incorporation of biosimilar products into the U.S. marketplace was designed to improve patient access and decrease healthcare costs. While much has evolved since the enactment of the BPCIA, the traditional barriers remain.
Now, more than ever, strategies to overcome these barriers are essential to improve the understanding of biosimilar products in the United States. The need for a solid guiding framework becomes more critical than ever before.
The next decade will see more litigation in this sphere. Further, and to an increasing extent, IPR proceedings challenging patents protecting biologic medicines, including IPRs filed before any action was taken under the BPCIA. Finally, the future will usher in considerable changes growing the scope of products that are regulated and litigated under the BPCIA.
Join the “who’s who” of the biosimilars and innovator biologics industries as they gather virtually to discuss and contemplate the impact of these critical developments.
Testimonials
I really enjoyed both days completely. Thank you for recruiting excellent speakers, and being thoughtful about the program. Well done!
